Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cleveland BioLabs stock | $2.74

Own Cleveland BioLabs stock in just a few minutes.

Fact checked

Cleveland BioLabs, Inc is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 7 staff and has a trailing 12-month revenue of around USD$631,842.

How to buy shares in Cleveland BioLabs

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cleveland BioLabs. Find the stock by name or ticker symbol: CBLI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cleveland BioLabs reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.74, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cleveland BioLabs, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cleveland BioLabs. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cleveland BioLabs share price

Use our graph to track the performance of CBLI stocks over time.

Cleveland BioLabs shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$2.74
52-week rangeUSD$0.515 - USD$4.65
50-day moving average USD$3.0591
200-day moving average USD$2.4721
Wall St. target priceUSD$2
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.268

Buy Cleveland BioLabs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cleveland BioLabs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cleveland BioLabs price performance over time

Historical closes compared with the close of $2.74 from 2020-12-09

1 week (2021-01-12) -26.74%
1 month (2020-12-18) -3.52%
3 months (2020-10-19) 26.27%
6 months (2020-07-17) 1.11%
1 year (2020-01-17) 156.07%
2 years (2019-01-18) 87.67%
3 years (2018-01-19) 3.74
5 years (2016-01-19) 3.32

Cleveland BioLabs financials

Revenue TTM USD$631,842
Gross profit TTM USD$-543,006
Return on assets TTM -47.85%
Return on equity TTM -110.49%
Profit margin 0%
Book value $-0.257
Market capitalisation USD$48.4 million

TTM: trailing 12 months

Shorting Cleveland BioLabs shares

There are currently 247,530 Cleveland BioLabs shares held short by investors – that's known as Cleveland BioLabs's "short interest". This figure is 7.2% down from 266,787 last month.

There are a few different ways that this level of interest in shorting Cleveland BioLabs shares can be evaluated.

Cleveland BioLabs's "short interest ratio" (SIR)

Cleveland BioLabs's "short interest ratio" (SIR) is the quantity of Cleveland BioLabs shares currently shorted divided by the average quantity of Cleveland BioLabs shares traded daily (recently around 124386.93467337). Cleveland BioLabs's SIR currently stands at 1.99. In other words for every 100,000 Cleveland BioLabs shares traded daily on the market, roughly 1990 shares are currently held short.

However Cleveland BioLabs's short interest can also be evaluated against the total number of Cleveland BioLabs shares, or, against the total number of tradable Cleveland BioLabs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cleveland BioLabs's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cleveland BioLabs shares in existence, roughly 20 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable Cleveland BioLabs shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cleveland BioLabs.

Find out more about how you can short Cleveland BioLabs stock.

Cleveland BioLabs share dividends

We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.

Have Cleveland BioLabs's shares ever split?

Cleveland BioLabs's shares were split on a 1:20 basis on 28 January 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.

Cleveland BioLabs share price volatility

Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $0.515 up to $4.65. A popular way to gauge a stock's volatility is its "beta".

CBLI.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.705. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).

Cleveland BioLabs overview

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site